Ultra-low-dose computed tomography (ULDCT) may have similar efficacy as low-dose CT (LDCT) for detecting a variety of pulmonary conditions in people with current or past smoking histories, but had poor detection of ground glass opacification lesions, according to a recent prospective study presented at the Radiological Society of North America (RSNA) conference.
In a recent poster presentation at the Radiological Society of North America (RSNA) conference, researchers shared preliminary findings from a prospective trial that compared the use of ultra-low-dose computed tomography (ULDCT) to low-dose CT (LDCT) in current smokers and those with a previous smoking history.
For the study, researchers examined the use of LDCT dosing (mean effective radiation dose of 1.40 mSv) versus ULDCT dosing (mean effective radiation dose of 0.39 mSv) in consecutive patients referred for lung cancer screening over a one-month period. The study cohort included current and previous smokers with a 20 pack-year history, according to the study. The researchers noted that 58 of the 265 enrolled patients had abnormal CT scans. The CT scans were reviewed by two senior thoracic radiologists.
The study authors found a 92 percent agreement between ULDCT and LDCT for emphysema and a 91 percent agreement for pulmonary nodules. Agreement for findings such as bronchial wall thickening, atelectasis and bronchiectasis ranged between 80 to 90 percent, according to the study.
However, the researchers noted that agreement between ULDCT and LDCT ranged between 60 to 80 percent for septal thickening, pleural effusion, and consolidation. They also noted poor agreement (37 percent) for ground glass opacification (GGO) lesions.
While the researchers noted the use of ULDCT could reduce effective radiation dosing to a third of that used for LDCT, they said the significant potential for missing other lung cancers such as lepidic adenocarcinoma outweigh the benefits of reduced radiation dosing.
“Despite the exciting agreement for some pulmonary findings, these results question whether using an ULDCT protocol for (lung cancer screening) would be adequate as many subsolid or GGO lesions could be missed,” wrote Matheus Zanon, MD, MSc, who is affiliated with the Department of Radiology at Pontificia Universidade Catolica do Rio Grande do Sul in Porto Alegre, Brazil, and colleagues.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.